Cosmos Health stock fell 1.58 percent as brands expand globally

Published on 10/05/2026 at 15:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cosmos Health stock fell 1.58 percent on October 2, while the company outlined sales across more than 40 countries. Q2 revenue reached USD 19.32 million.

COSM, US2214133058, Illustration mit AI erstellt.

Cosmos Health stock (ISIN US2214133058) closed at USD 0.38 on October 2, 2026, down 1.58 percent from the prior close. The company used its October 1 update to outline a healthcare portfolio sold in more than 40 countries, giving investors a fresh measure of its commercial reach.

Brands reach more than 40 countries

According to StockTitan on October 1, 2026, Cosmos Health said its portfolio included more than 15 proprietary brands and 10 branded generics across five product categories. The products are distributed through pharmacies, hospitals, retail chains and e-commerce channels.

The same company update cited a contract-manufacturing production pipeline exceeding 32.7 million units. The pipeline is tied to Cana Laboratories, while the company also described manufacturing, pharmaceutical distribution, telehealth and research services as parts of its operating platform.

Revenue offers a measurable test

Cosmos Health reported second-quarter 2026 revenue of USD 19.32 million, compared with a consensus estimate of USD 18.99 million, according to MarketBeat. The USD 0.33 million gap between actual revenue and consensus provides a clearer operating comparison than the geographic expansion headline alone.

MarketBeat also reported adjusted earnings per share of negative USD 0.10 for Q2 2026, matching the consensus estimate of negative USD 0.10. The combination of a revenue beat and an earnings result in line with expectations leaves revenue conversion and profitability as separate measures for assessing the company.

Small-cap valuation remains visible

COSM had a market capitalization of USD 20.7 million as of October 2, 2026. Its 52-week range was USD 0.16 to USD 1.32, placing the closing price materially closer to the yearly low than the yearly high.

The market capitalization gives the operating updates a small-cap context: the company cited more than 32.7 million manufacturing units and second-quarter revenue of USD 19.32 million, while the equity value stood at USD 20.7 million. Those figures describe different dimensions of the business and should not be treated as equivalent measures.

Stock closed at USD 0.38

Cosmos Health stock closed at USD 0.38 on Nasdaq on October 2, 2026, with a daily change of negative 1.58 percent. The next market test is whether the reported revenue and manufacturing pipeline translate into sustained earnings improvement.